Hudson Bay Capital Management
CORT icon

Hudson Bay Capital Management’s Corcept Therapeutics CORT Stock Holding History

Hudson Bay Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-185,800
Closed -$6.47M – 1436
2025
Q4 		$6.47M Buy
+185,800
New +$14.6M 0.02% 431
2025
Q3 		– Sell
-8,140
Closed -$597K – 1318
2025
Q2 		$597K Buy
+8,140
New +$590K ﹤0.01% 1053
2024
Q2 		– Sell
-47,569
Closed -$1.2M – 804
2024
Q1 		$1.2M Buy
+47,569
New +$1.12M 0.01% 528

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Hudson Bay Capital Management's CORT Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 185,800 shares — an estimated $6.47M sold.

Hudson Bay Capital Management first reported a position in CORT in Q1 2024 and held it in 3 quarters. The position peaked at $6.47M in Q4 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 185,800 Corcept Therapeutics shares in Q1 2026, an estimated $6.47M.
  • Hudson Bay Capital Management first reported a position in Corcept Therapeutics in Q1 2024 and held it in 3 quarters.
  • Hudson Bay Capital Management's Corcept Therapeutics position peaked at $6.47M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.